BioCentury
ARTICLE | Company News

Cellceutix, Pioneer Valley Life Sciences Institute deal

December 19, 2011 8:00 AM UTC

The parties partnered to research Cellceutix's Kevetrin to treat tumors associated with mitochondrial dysfunction due to aging. Kevetrin is a small molecule protein kinase B (PKB; PKBA; AKT; AKT1) inhibitor that also acts as an alkylating agent and leukotriene B4 (LTB4) inhibitor with anti-angiogenic properties. Last week, Cellceutix said FDA reviewed an IND for Kevetrin and advised it that the batch formulation needs to be redone after operations were ceased at contract manufacturer Formatech Inc. (Andover, Mass.). Cellceutix said it already has identified an alternative formulation site, with production slated for next month. Details were not disclosed. ...